Genzyme, a Sanofi company, on Friday announced that the Food and Drug Administration approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis.
The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.
The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.
Drug maker Genzyme plans to present data from trial programs of two multiple sclerosis drugs at the American Academy of Neurology's annual meeting in New Orleans, which starts this Saturday and lasts until next Saturday.
A pharmacy benefit manager and the U.S. subsidiary of a German drug maker have made a deal concerning a drug for multiple sclerosis.
The Food and Drug Administration has approved two separate dosing innovations for multiple sclerosis patients that are being treated with a Biogen Idec drug.
An orally administered drug made by Genzyme for treating multiple sclerosis did not appear superior to a biotech drug already on the market, according to results of a late-stage clinical trial.
A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.
Multiple sclerosis patients treated with a drug made by Teva Pharmaceutical Industries showed a "significant" reduction in their loss of brain volume, according to a new study.
Swiss biotech company Biogen Idec and U.S. drug maker Abbott have begun enrolling patients in...
Swiss drug maker Biogen Idec and Irish drug maker Elan Corp. have started enrolling patients...
An investigational drug for treating multiple sclerosis reduced progression of disability by more than 30%,...